Premium
The antagonism of benzodiazepine withdrawal effects by the selective cholecystokinin B receptor antagonist CI‐988
Author(s) -
Singh Lakhbir,
Field Mark J.,
Vass Caroline A.,
Hughes John,
Woodruff Geoffrey N.
Publication year - 1992
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1992.tb14201.x
Subject(s) - cholecystokinin , diazepam , discontinuation , antagonism , antagonist , benzodiazepine , pharmacology , receptor antagonist , medicine , endocrinology , receptor , chemistry
The ability of a selective cholecystokinin B (CCK B ) receptor antagonist, CI‐988, to block benzodiazepine withdrawal effects was examined in mice. The discontinuation of twice daily administration of diazepam (1 mg kg −1 , i.p.) induced withdrawal anxiogenesis and a proconvulsant effect. In contrast, no such effects were seen following withdrawal from similar administration of CI‐988. However, CI‐988 dose‐dependently (0.001–1.0 mg kg −1 , s.c.) antagonized both the anxiogenesis and the proconvulsant effect following diazepam‐withdrawal.